International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer.

ABSTRACT:

Background

The recently conducted ADRIATIC trial demonstrated that adding durvalumab led to significant improvements in the survival of non-advanced limited-stage small cell lung cancer (LS-SCLC) following concurrent chemoradiotherapy (CCRT). While efficacious, immunotherapeutic drugs are associated with high costs. Therefore, the purpose of this study is to conduct pharmacoeconomic analyses of the cost-effectiveness of durvalumab consolidation treatment after CCRT for LS-SCLC from the perspective of payers in specific countries.

Methods

The costs and efficacy of consolidation durvalumab versus placebo treatment following CCRT for LS-SCLC patients were analyzed using a three-state Markov model. The lifetime direct medical costs, incremental cost-effectiveness ratios (ICERs),

SUBMITTER: Liu K 

PROVIDER: S-EPMC12432599 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature